The companies are planning to submit Ruconest biologics license application (BLA) within the first six months of 2013 to the FDA.
Upon the acceptance of BLA for FDA review, Pharming will earn additional $5m as milestone payment.
Pharming CEO Sijmen de Vries said, "We are pleased to have received this US$10 million milestone from our partner Santarus, which significantly strengthens our balance sheet and signals the beginning of a new chapter in the development of the Company."
Ruconest investigational drug, produced by leveraging Pharming’s technology in milk of transgenic rabbits, is a recombinant version of the human protein C1 inhibitor.